This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Child Health and Human Development (NICHD) to Westat, Inc., a prominent professional services firm. The contract, with a ceiling value of $1,125,154.00, requires Westat to coordinate, maintain, and manage NICHD participating sites for IMPAACT 2041, a Phase I/II study on the pharmacokinetics and safety of the hepatitis C drug combination of glecaprevir/pibrentasvir initiated in pregnancy, with and without HIV. This contract is part of a larger $175 million Indefinite Delivery Vehicle (IDV) between NICHD and Westat for international and domestic pediatric HIV studies. The contract does not have a set-aside designation and is scheduled for completion by July 31, 2028.
Generated 3/8/25, 9:43 AM